Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Mirum has it all to do after Albireo gets a result with lead project odevixibat in a rare childhood liver disease.